Key result
The cardiac intracellular renin-angiotensin system is significantly upregulated in diabetes and is associated with cardiac dysfunction, presenting a potential target for novel therapeutic strategies.
The intracellular renin-angiotensin system represents a distinct pathophysiological mechanism in diabetic cardiac dysfunction that may require novel targeted therapeutic strategies.
Intracellular RAS distinctions may limit current inhibitor efficacy; leaves open distinct mechanistic targets for validation.
The renin-angiotensin system (RAS) has mainly been categorized as a circulating and a local tissue RAS. A new component of the local system, known as the intracellular RAS, has recently been described. The intracellular RAS is defined as synthesis and action of ANG II intracellularly. This RAS appears to differ from the circulating and the local RAS, in terms of components and the mechanism of action. These differences may alter treatment strategies that target the RAS in several pathological conditions. Recent work from our laboratory has demonstrated significant upregulation of the cardiac, intracellular RAS in diabetes, which is associated with cardiac dysfunction. Here, we have reviewed evidence supporting an intracellular RAS in different cell types, ANG II's actions in cardiac cells, and its mechanism of action, focusing on the intracellular cardiac RAS in diabetes. We have discussed the significance of an intracellular RAS in cardiac pathophysiology and implications for potential therapies.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2011) conducted a review in Diabetes and cardiac dysfunction. Intracellular renin-angiotensin system (RAS) was evaluated. The cardiac intracellular renin-angiotensin system is significantly upregulated in diabetes and is associated with cardiac dysfunction, presenting a potential target for novel therapeutic strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: